Cardinal Health stock soars to all-time high of $158.1

Cardinal Health Inc (NYSE:CAH). shares have reached an unprecedented peak, touching an all-time high of $158.1. This milestone underscores a period of robust performance for the healthcare services company, which has seen its stock value surge by 57.85% over the past year. With a market capitalization of $37.64 billion and an impressive track record of 43 consecutive years of dividend payments, Cardinal Health has demonstrated remarkable stability. According to InvestingPro analysis, the stock currently appears undervalued, suggesting potential for further gains. Investors have rallied behind Cardinal Health, buoyed by the company’s strategic initiatives and strong market position, which have collectively propelled the stock to new heights. The impressive one-year change reflects a growing confidence in Cardinal Health’s prospects and its ability to navigate the complex healthcare landscape. InvestingPro data reveals the company maintains a "GREAT" overall financial health score of 3.26, with 14 additional key insights available to subscribers.

In other recent news, Cardinal Health has raised its full-year adjusted earnings per share (EPS) forecast, now expecting $8.15 to $8.20, surpassing previous guidance and exceeding the average analyst estimate of $8.14. The company also provided preliminary guidance for fiscal year 2026, projecting adjusted EPS of $9.10 to $9.30, indicating a 13% growth at the midpoint. During its Investor Day, Cardinal Health outlined its growth strategy, including a long-term target of 12% to 14% compound annual growth rate for adjusted EPS from fiscal years 2026 through 2028. Additionally, the company announced strategic initiatives such as the launch of The Specialty Alliance multi-specialty MSO platform and investments in Biopharma Solutions. Analyst firm TD Cowen reiterated its Buy rating on Cardinal Health stock, maintaining a $162.00 price target, while BofA Securities increased its price target to $170.00, citing expectations of sustainable double-digit EPS growth. In another development, Cardinal Health entered a distribution agreement with Citius Oncology to facilitate the U.S. launch of LYMPHIR™, an FDA-approved immunotherapy. This partnership is expected to enhance the availability and delivery of the treatment, marking a significant step for Citius Oncology.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.